Home › Research › Biomarkers
Myo-inositol as a spectroscopic marker of neuroinflammation in frontotemporal lobar degeneration
Tan, S. Y.; Naessens, M.; Jones, P. S.; Todd, E. G.; Williams, R. S.; Rodgers, C. T.; Hughes, L. E.; Shapiro et al.. medRxiv (preprint), 2026-09-20
Topic: Brain proteins, microglia and lab models
Plain-language summary
We focus on neuroinflammation in disorders associated with frontotemporal lobar degeneration (FTLD). ResultsMyo-inositol was elevated in the R IFG ({beta} = 0.20, t = 5.10, p = 8.8 x 10^-7) but not in the R OCC ({beta} = 0.05, t = 1.36, p = 0.18), in people with FTLD versus controls. In FTLD, myo-inositol in the R IFG was positively associated with a peripheral inflammatory profile characterised by IL-6, IL-1{beta}, GFAP, CSF2, CRP, and CCL22 ({beta} = 0.39, t = 5.12, p = 3.60 x 10^-6). R IFG myo-inositol was negatively associated with ACE-R performance in patients ({beta} = -44.59, t = -4.12, p = 0.00016). Elevated levels in disease-affected regions were associated with peripheral markers of inflammation (reflecting astrocytosis and microgliosis) and with cognitive impairment.
What this study adds
Evidence grade: Low
This study found that a brain chemical marker, myo-inositol, was elevated in a disease-affected brain region in people with frontotemporal lobar degeneration and was linked to inflammation markers and worse cognitive scores. It is research into measuring neuroinflammation, not a treatment or cure.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Tan, S. Y., Naessens, M., Jones, P. S., Todd, E. G., Williams, R. S., Rodgers, C. T., et al. (2026). Myo-inositol as a spectroscopic marker of neuroinflammation in frontotemporal lobar degeneration. medRxiv (preprint). https://doi.org/10.64898/2026.09.18.26363386
Vancouver
Tan SY, Naessens M, Jones PS, Todd EG, Williams RS, Rodgers CT, et al. Myo-inositol as a spectroscopic marker of neuroinflammation in frontotemporal lobar degeneration. medRxiv (preprint). 2026. doi:10.64898/2026.09.18.26363386.
BibTeX
@article{tan2026-e830449b,
author = {Tan, S. Y. and Naessens, M. and Jones, P. S. and Todd, E. G. and Williams, R. S. and Rodgers, C. T. and Hughes, L. E. and Shapiro and others},
title = {{Myo-inositol as a spectroscopic marker of neuroinflammation in frontotemporal lobar degeneration}},
journal = {medRxiv (preprint)},
year = {2026},
doi = {10.64898/2026.09.18.26363386},
url = {https://doi.org/10.64898/2026.09.18.26363386}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We focus on neuroinflammation in disorders associated with frontotemporal lobar degeneration (FTLD).
- ResultsMyo-inositol was elevated in the R IFG ({beta} = 0.20, t = 5.10, p = 8.8 x 10^-7) but not in the R OCC ({beta} = 0.05, t = 1.36, p = 0.18), in people with FTLD versus controls.
- In FTLD, myo-inositol in the R IFG was positively associated with a peripheral inflammatory profile characterised by IL-6, IL-1{beta}, GFAP, CSF2, CRP, and CCL22 ({beta} = 0.39, t = 5.12, p = 3.60 x 10^-6).
- R IFG myo-inositol was negatively associated with ACE-R performance in patients ({beta} = -44.59, t = -4.12, p = 0.00016).
- Elevated levels in disease-affected regions were associated with peripheral markers of inflammation (reflecting astrocytosis and microgliosis) and with cognitive impairment.
Why it matters
This study found that a brain chemical marker, myo-inositol, was elevated in a disease-affected brain region in people with frontotemporal lobar degeneration and was linked to inflammation markers and worse cognitive scores. It is research into measuring neuroinflammation, not a treatment or cure.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 24 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 23 of the 94 points we could judge it on, which is 24 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv (preprint)) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author James Benedict Rowe: h-index 101 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 9 institution(s) in 3 countries |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 23 / 94 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 23 of the 94 points we could judge it on is 24 out of 100. |
| Total | 24 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “tdp-43”
1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.